150 related articles for article (PubMed ID: 32683462)
1. Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies.
Ferro M; Lucarelli G; de Cobelli O; Vartolomei MD; Damiano R; Cantiello F; Crocerossa F; Perdonà S; Del Prete P; Cordima G; Musi G; Del Giudice F; Busetto GM; Chung BI; Porreca A; Ditonno P; Battaglia M; Terracciano D
World J Urol; 2021 Jun; 39(6):1861-1867. PubMed ID: 32683462
[TBL] [Abstract][Full Text] [Related]
2. Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies.
Ferro M; Terracciano D; Musi G; de Cobelli O; Vartolomei MD; Damiano R; Cantiello F; Buonerba C; Morelli M; Mistretta FA; Luzzago S; Perdonà S; Del Prete P; Del Giudice F; Busetto GM; Porreca A; Autorino R; Manfredi M; Porpiglia F; Muto M; Loizzo D; Ditonno P; Battaglia M; Lucarelli G
Urol Int; 2022; 106(1):75-82. PubMed ID: 34167120
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy.
Takeshima Y; Yamada Y; Teshima T; Fujimura T; Kakutani S; Hakozaki Y; Kimura N; Akiyama Y; Sato Y; Kawai T; Yamada D; Kume H
BMC Cancer; 2021 May; 21(1):501. PubMed ID: 33947348
[TBL] [Abstract][Full Text] [Related]
4. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
[TBL] [Abstract][Full Text] [Related]
5. Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine.
Capogrosso P; Ventimiglia E; Moschini M; Boeri L; Farina E; Finocchio N; Gandaglia G; Fossati N; Briganti A; Montorsi F; Salonia A
Prostate; 2017 Feb; 77(2):234-241. PubMed ID: 27775173
[TBL] [Abstract][Full Text] [Related]
6. Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.
Takeuchi N; Sakamoto S; Nishiyama A; Horikoshi T; Yamada Y; Iizuka J; Maimaiti M; Imamura Y; Kawamura K; Imamoto T; Komiya A; Ikehara Y; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2018 Aug; 16(4):e817-e829. PubMed ID: 29576444
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up.
Grogan J; Gupta R; Mahon KL; Stricker PD; Haynes AM; Delprado W; Turner J; Horvath LG; Kench JG
BJU Int; 2017 Nov; 120(5):651-658. PubMed ID: 28371244
[TBL] [Abstract][Full Text] [Related]
8. Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy.
Porcaro AB; Tafuri A; Sebben M; Processali T; Pirozzi M; Shakir A; Amigoni N; Rizzetto R; Brunelli M; Migliorini F; Siracusano S; Artibani W
Int Urol Nephrol; 2019 Dec; 51(12):2169-2180. PubMed ID: 31444696
[TBL] [Abstract][Full Text] [Related]
9. Role of prostate health index to predict Gleason score upgrading and high-risk prostate cancer in radical prostatectomy specimens.
Kim H; Jung G; Kim JH; Byun SS; Hong SK
Sci Rep; 2021 Aug; 11(1):17447. PubMed ID: 34465825
[TBL] [Abstract][Full Text] [Related]
10. Late biochemical recurrence after radical prostatectomy is associated with a slower rate of progression.
Chow K; Herrera P; Stuchbery R; Peters JS; Costello AJ; Hovens CM; Corcoran NM
BJU Int; 2019 Jun; 123(6):976-984. PubMed ID: 30248237
[TBL] [Abstract][Full Text] [Related]
11. The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection.
Porcaro AB; Panunzio A; Tafuri A; Cerrato C; Gallina S; Bianchi A; Rizzetto R; Amigoni N; Gozzo A; Serafin E; Cianflone F; Migliorini F; Vidiri S; Di Filippo G; Novella G; Brunelli M; Shakir A; Pagliarulo V; Cerruto MA; Siracusano S; Antonelli A
Urol Int; 2022; 106(9):928-939. PubMed ID: 35081537
[TBL] [Abstract][Full Text] [Related]
12. Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1-2 prostate cancer at MRI-targeted biopsy: a multicenter analysis.
Kesch C; Pantea V; Soeterik T; Marquis A; la Bombarda G; Morlacco A; Barletta F; Radtke JP; Darr C; Preisser F; Zattoni F; Marra G; van den Bergh RCN; Hadaschik B; Gandaglia G;
World J Urol; 2023 Feb; 41(2):427-434. PubMed ID: 36534151
[TBL] [Abstract][Full Text] [Related]
13. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
Ferro M; Lucarelli G; Bruzzese D; Di Lorenzo G; Perdonà S; Autorino R; Cantiello F; La Rocca R; Busetto GM; Cimmino A; Buonerba C; Battaglia M; Damiano R; De Cobelli O; Mirone V; Terracciano D
Oncotarget; 2017 Mar; 8(11):18424-18434. PubMed ID: 27793023
[TBL] [Abstract][Full Text] [Related]
14. Preoperative endogenous total testosterone predicts prostate cancer progression: results in 580 consecutive patients treated with robot assisted radical prostatectomy for clinically localized disease.
Porcaro AB; Panunzio A; Serafin E; Bianchi A; Gallina S; Mazzucato G; Vidiri S; D'Aietti D; Orlando R; Ditonno F; Montanaro F; Marafioti Patuzzo G; Bailelli A; Artoni F; Zecchini Antoniolli S; Rizzetto R; Brunelli M; Siracusano S; Cerruto MA; Tafuri A; Antonelli A
Int Urol Nephrol; 2023 May; 55(5):1139-1148. PubMed ID: 36943597
[TBL] [Abstract][Full Text] [Related]
15. The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading - a matched-pair analysis.
Berg KD; Thomsen FB; Nerstrøm C; Røder MA; Iversen P; Toft BG; Vainer B; Brasso K
BJU Int; 2016 Jun; 117(6):883-9. PubMed ID: 26823232
[TBL] [Abstract][Full Text] [Related]
16. The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.
Porcaro AB; Caruso B; Terrin A; De Luyk N; Cacciamani G; Corsi P; Inverardi D; De Marchi D; Baldassarre R; Cerruto M; Ghimenton C; Brunelli M; Zecchini Antoniolli S; Petrozziello A; Artibani W
Arch Ital Urol Androl; 2016 Mar; 88(1):17-22. PubMed ID: 27072171
[TBL] [Abstract][Full Text] [Related]
17. Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer.
Sanguedolce F; Falagario UG; Castellan P; Di Nauta M; Silecchia G; Bruno SM; Russo D; Treacy PJ; Tewari AK; Montironi R; Carrieri G; Cormio L
Urol Oncol; 2020 Oct; 38(10):793.e19-793.e25. PubMed ID: 32220548
[TBL] [Abstract][Full Text] [Related]
18. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy.
Yamamoto S; Yonese J; Kawakami S; Ohkubo Y; Tatokoro M; Komai Y; Takeshita H; Ishikawa Y; Fukui I
Eur Urol; 2007 Sep; 52(3):696-701. PubMed ID: 17412490
[TBL] [Abstract][Full Text] [Related]
20. Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results.
Neuzillet Y; Raynaud JP; Dreyfus JF; Radulescu C; Rouanne M; Schneider M; Krish S; Rouprêt M; Drouin SJ; Comperat E; Galiano M; Cathelineau X; Validire P; Molinié V; Fiet J; Giton F; Lebret T; Botto H
Horm Cancer; 2019 Feb; 10(1):36-44. PubMed ID: 30293206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
